| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 3.23 | 122.8% |
| Total Income | 3.23 | 122.8% |
| Expenditure | 25.93 | 32.4% |
| PBT | — | |
| Net Profit | -18.33 | 22.3% |
| OPM | — | |
| NPM | — | |
| EPS | -0.38 | 98.0% |
Aktis Oncology Reports Q1 2026 Financial Results and Business Highlights
12 May 2026 · 12 May, 1:38 am
Summary
Aktis Oncology reported financial results and business highlights for the first quarter ended March 31, 2026. The company's cash, cash equivalents and marketable securities were $538.5 million as of March 31, 2026. Collaboration revenue increased to $3.2 million compared to $1.4 million in the prior year period. The net loss for the quarter was $18.3 million, compared to $15.0 million for the comparable prior year period. The company expects its cash, cash equivalents and marketable securities as of March 31, 2026 to fund its operations into 2029.
Key Highlights
- 1
Aktis Oncology announced a two-trial clinical development strategy for AKY-2519, enabling evaluation in multiple patient segments.
- 2
The company initiated a Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC), with preliminary data expected in 2027.
- 3
Clinical imaging and dosimetry data presentation for AKY-2519 was announced for the upcoming 2026 ASCO Annual Meeting.
- 4
Patients with Nectin-4 expressing tumors are being enrolled in the ongoing Phase 1b clinical trial of AKY-1189, with preliminary data expected in the first quarter of 2027.
- 5
Cash, cash equivalents and marketable securities were $538.5 million as of March 31, 2026, compared to $226.8 million as of December 31, 2025.
- 6
Collaboration revenue was $3.2 million for the quarter ended March 31, 2026, compared to $1.4 million for the comparable prior year period.
- 7
Net loss was $18.3 million for the quarter ended March 31, 2026, compared to $15.0 million for the comparable prior year period.
Management Comments
Matthew Roden
Ph.D.
"We continue to build momentum toward delivering a new class of radiopharmaceuticals targeting tumor types with large patient populations, leveraging our differentiated miniprotein radioconjugate platform and patient-first end-to-end supply chain." “Last week, we announced the initiation of our Phase 1b clinical trial of AKY-2519 in patients with mCRPC. This is the first of two trials in our clinical development strategy designed to expand the breadth of tumors studied and augment speed to data, with preliminary data from the mCRPC trial anticipated in 2027. We plan to initiate a second Phase 1b basket trial of AKY-2519 in additional solid tumors in the second half of this year. We also look forward to presenting our first AKY-2519 clinical imaging and dosimetry data for AKY-2519 at ASCO, which informed our clinical development strategy.” “AKY-2519 marks the second program we have advanced from our proprietary miniprotein radioconjugate platform to the clinic in the last twelve months. In parallel, we continue to enroll patients in our ongoing Phase 1b trial of AKY-1189 targeting Nectin-4 expressing tumors, with preliminary data expected in the first quarter of 2027. We remain focused on generating clinical data intended to support advancement of both programs and maximizing the potential clinical benefit for patients.”
Informational and educational content only. Not investment advice.